— Know what they know.
Not Investment Advice

OGN NYSE

Organon & Co.
1W: -0.1% 1M: +0.1% 3M: +1.6% YTD: +90.4% 1Y: +50.4% 3Y: -3.4% 5Y: -52.4%
$13.75
+0.01 (+0.07%)
 
Weekly Expected Move ±0.5%
$14 $14 $14 $14 $14
NYSE · Healthcare · Drug Manufacturers - General · Tech Score Neutral · Power 52 · $3.6B mcap · 261M float · 0.992% daily turnover · Short 46% of daily vol
Credit Risk of going bust: higher than 87% of companies Debt: 70.3% of company value Bonds: $567.6M held by 309 funds, 116 bp over Treasuries → details ▾
Of US companies ranked in the second-riskiest tenth, about 1 in 87 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $2.24 (down 84%), Organon & Co. would be worth roughly what it owes.
Total debt $8.55B against a stock market value of $3.61B.
Distance to default 1.98 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $4.31B (short-term plus half of long-term), stock volatility 62.2%; Altman Z 1.25. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.

Balance Sheet Trends

Total Assets
$12.9B -1.8% ▼
5Y CAGR: +4.9%
Total Liabilities
$12.1B -4.1% ▼
5Y CAGR: +21.2%
Shareholders Equity
$752M +59.3% ▲
5Y CAGR: -32.8%
Cash & Investments
$574M -15.0% ▼
5Y CAGR: +116.7%
Total Debt
$8.8B -2.6% ▼
5Y CAGR: +209.5%
Net Debt
$8.2B -1.6% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$737M$706M$693M$675M$574M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$737M$706M$693M$675M$574M
Net Receivables$1.5B$1.6B$1.9B$1.5B$1.4B
Inventory$915M$1.0B$1.3B$1.3B$0
Other Current Assets$596M$616M$643M$861M$2.3B
Total Current Assets$3.8B$3.9B$4.5B$4.3B$4.4B
Property, Plant & Equip.$1.2B$1.2B$1.4B$1.3B$0
Goodwill & Intangibles$5.3B$5.3B$5.1B$6.1B$5.3B
Long-Term Investments$0$0$0$27M$0
Other Non-Current Assets$464M$272M$250M$361M$3.2B
Total Non-Current Assets$6.9B$7.0B$7.5B$8.8B$8.5B
Total Assets$10.7B$11.0B$12.1B$13.1B$12.9B
— Liabilities —
Accounts Payable$1.4B$1.1B$1.3B$1.2B$952M
Short-Term Debt$55M$57M$55M$64M$56M
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$975M$1.1B$1.3B$1.4B$1.3B
Total Current Liabilities$2.6B$2.5B$2.9B$2.7B$2.4B
Long-Term Debt$9.1B$8.9B$8.8B$8.9B$8.6B
Other Non-Current Liab.$279M$261M$287M$865M$924M
Total Non-Current Liabilities$9.6B$9.3B$9.2B$9.9B$9.7B
Total Liabilities$12.2B$11.8B$12.1B$12.6B$12.1B
— Equity —
Common Stock$3M$3M$3M$3M$3M
Retained Earnings-$998M-$331M$443M$1.0B$1.1B
Accumulated OCI-$513M-$564M-$541M-$649M-$527M
Total Stockholders Equity-$1.5B-$892M-$70M$472M$752M
Total Liabilities & Equity$10.7B$11.0B$12.1B$13.1B$12.9B
— Key Metrics —
Total Debt$9.4B$9.1B$8.9B$9.0B$8.8B
Net Debt$8.6B$8.4B$8.2B$8.4B$8.2B
Total Investments$0$0$0$27M$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms